Literature DB >> 11668071

Hyperglycemia reduces coronary collateral blood flow through a nitric oxide-mediated mechanism.

J R Kersten1, W G Toller, J P Tessmer, P S Pagel, D C Warltier.   

Abstract

We tested the hypothesis that hyperglycemia alters retrograde coronary collateral blood flow by a nitric oxide-mediated mechanism in a canine Ameriod constrictor model of enhanced collateral development. Administration of 15% dextrose to increase blood glucose concentration to 400 or 600 mg/dl decreased retrograde blood flow through the left anterior descending coronary artery to 78 +/- 9 and 82 +/- 8% of baseline values, respectively. In contrast, saline or L-arginine (400 mg x kg(-1) x h(-1)) had no effect on retrograde flow. Coronary hypoperfusion and 1 h of reperfusion decreased retrograde blood flow similarly in saline- or L-arginine-treated dogs (76 +/- 11 and 89 +/- 4% of baseline, respectively), but these decreases were more pronounced in hyperglycemic dogs (47 +/- 10%). L-arginine prevented decreases in retrograde coronary collateral blood flow during hyperglycemia (100 +/- 5 and 95 +/- 6% of baseline at blood glucose concentrations of 400 and 600 mg/dl, respectively) and after coronary hypoperfusion and reperfusion (84 +/- 14%). The results suggest that hyperglycemia decreases retrograde coronary collateral blood flow by adversely affecting nitric oxide availability.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11668071     DOI: 10.1152/ajpheart.2001.281.5.H2097

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  19 in total

1.  Predictors and long-term prognosis of angiographic slow/no-reflow phenomenon during emergency percutaneous coronary intervention for ST-elevated acute myocardial infarction.

Authors:  Li Dong-bao; Hua Qi; Liu Zhi; Wang Shan; Jin Wei-ying
Journal:  Clin Cardiol       Date:  2010-12       Impact factor: 2.882

2.  Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetes.

Authors:  Karin Przyklenk; Michelle Maynard; Dale L Greiner; Peter Whittaker
Journal:  Antioxid Redox Signal       Date:  2010-10-06       Impact factor: 8.401

3.  Impact of hyperglycemia at admission in patients with acute ST-segment elevation myocardial infarction as assessed by contrast-enhanced MRI.

Authors:  Christoph J Jensen; Holger C Eberle; Kai Nassenstein; Thomas Schlosser; Mani Farazandeh; Christoph K Naber; Georg V Sabin; Oliver Bruder
Journal:  Clin Res Cardiol       Date:  2011-02-24       Impact factor: 5.460

Review 4.  Neuroendocrine System Regulatory Mechanisms: Acute Coronary Syndrome and Stress Hyperglycaemia.

Authors:  Ricardo A Perez de la Hoz; Sandra Patricia Swieszkowski; Federico Matias Cintora; Jose Martin Aladio; Claudia Mariana Papini; Maia Matsudo; Alejandra Silvia Scazziota
Journal:  Eur Cardiol       Date:  2018-08

5.  Major impact of admission glycaemia on 30 day and one year mortality in non-diabetic patients admitted for myocardial infarction: results from the nationwide French USIC 2000 study.

Authors:  Z Kadri; N Danchin; L Vaur; Y Cottin; P Guéret; M Zeller; J-M Lablanche; D Blanchard; G Hanania; N Genès; J-P Cambou
Journal:  Heart       Date:  2005-12-09       Impact factor: 5.994

Review 6.  Efficacy of cardioprotective 'conditioning' strategies in aging and diabetic cohorts: the co-morbidity conundrum.

Authors:  Karin Przyklenk
Journal:  Drugs Aging       Date:  2011-05-01       Impact factor: 3.923

7.  Clinical and angiographic features associated with coronary collateralization in stable angina patients with chronic total occlusion.

Authors:  Zhen Sun; Ying Shen; Lin Lu; Rui-yan Zhang; Li-jin Pu; Qi Zhang; Zheng-kun Yang; Jian Hu; Qiu-jing Chen; Wei-feng Shen
Journal:  J Zhejiang Univ Sci B       Date:  2013-08       Impact factor: 3.066

8.  Early impact of insulin treatment on mortality for hyperglycaemic patients without known diabetes who present with an acute coronary syndrome.

Authors:  C Weston; L Walker; J Birkhead
Journal:  Heart       Date:  2007-05-13       Impact factor: 5.994

9.  DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome.

Authors:  Yochai Birnbaum; Dat Tran; Mandeep Bajaj; Yumei Ye
Journal:  Basic Res Cardiol       Date:  2019-08-06       Impact factor: 17.165

10.  The association between glycaemic control during hospitalization and risk of adverse events: A retrospective cohort study.

Authors:  Lan Deng; Wusiman Aibibula; Zahra Talat; Kristian B Filion; Shaun Eintracht; Kaberi Dasgupta; Vicky Tagalakis; Agnieszka Majdan; Oriana Hoi Yun Yu
Journal:  Endocrinol Diabetes Metab       Date:  2021-05-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.